Skip to main content

Juxtapid Side Effects

Generic name: lomitapide

Medically reviewed by Drugs.com. Last updated on Jun 8, 2023.

Note: This document contains side effect information about lomitapide. Some dosage forms listed on this page may not apply to the brand name Juxtapid.

Applies to lomitapide: oral capsule.

Warning

Oral route (Capsule)

Lomitapide mesylate can cause elevations in transaminases. Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of lomitapide mesylate if the ALT or AST is 3 times the ULN or greater. Discontinue lomitapide mesylate for clinically significant liver toxicity. Lomitapide mesylate increases hepatic fat (hepatic steatosis) with or without concomitant increases in transaminases. Hepatic steatosis associated with lomitapide mesylate may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Because of the risk of hepatotoxicity, lomitapide mesylate is available only through a restricted program called the Juxtapid® REMS Program. Prescribe lomitapide mesylate only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH). The safety and effectiveness of lomitapide mesylate have not been established in patients with hypercholesterolemia who do not have HoFH.

Serious side effects of Juxtapid

Along with its needed effects, lomitapide (the active ingredient contained in Juxtapid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lomitapide:

More common

Other side effects of Juxtapid

Some side effects of lomitapide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to lomitapide: oral capsule.

Cardiovascular

Very common (10% or more): Chest pain (24%), angina pectoris (10%), palpitations (10%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (79%), nausea (65%), dyspepsia (38%), vomiting (34%), abdominal pain (34%), abdominal discomfort (21%), abdominal distention (21%), constipation (21%), flatulence (21%), gastroesophageal reflux disease (10%), defecation urgency ((10%), rectal tenesmus (10%), gastroenteritis (14%)[Ref]

Hepatic

Very common (10% or more): Increased ALT (17%), at least one elevation in ALT and/or AST greater than or equal to 3 times ULN (29%), hepatic steatosis: of 23 patients in a study for 78 weeks, 18 (78%) exhibited an increase in hepatic fat greater than 5% and 3 (13%) exhibited an increase greater than 20%[Ref]

Immunologic

Very common (10% or more): Influenza (21%)[Ref]

Metabolic

Very common (10% or more): Weight loss (24%)[Ref]

Nervous system

Very common (10% or more): Fatigue (17%), fever (10%), headache (10%), dizziness (10%)[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (17%), pharyngolaryngeal pain (14%), nasal congestion (10%)[Ref]

Dermatologic

Common (1% to 10%): Ecchymosis, papule, rash erythematous, xanthoma[Ref]

Frequently asked questions

References

1. Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc. 2013.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.